Yes, whether Cormatrix is pulled by FDA or not, it is more than likely that CC will overtake it as the gold standard due to its durability, pliability, and lack of calcification. Julian has a target of $20M in sales in the next 2-3yrs.
We need to remember this is a platform technology and its use will expand into many cardio procedures outside of CHD, as well as non-cardio procedures.
I don't place a lot of value in quarterlies as my accounting skills are basic, it's the accruals that tell the whole picture.
Hey Lex, new keyboard mate? Good to see a bit of capex there
Yes, whether Cormatrix is pulled by FDA or not, it is more than...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
0.000(0.00%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.70 | $58.64K | 3.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 109 | $18.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.10 | 700 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |